Drugs / Fluzone HD influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07300085 | Nov 2025 → Dec 2026 expected | — | Cidara Therapeutics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzone HD influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07300085 ↗ |
| Known as | Fluzone High-Dose Influenza Vaccine | “A Phase 1, Double-blind, Randomized Trial to Evaluate Safety and Immunogenicity of Fluzone® High-Dose Influenza Vaccine When Concomitantly Administered With CD388” NCT07300085 ↗ |
| Modality | Vaccine | “Fluzone HD influenza vaccine” NCT07300085 ↗ |
| Route | Intramuscular | “Fluzone HD influenza vaccine by intramuscular (IM) injection” NCT07300085 ↗ |